The fact that everything looks different doesn't mean that all has changed...
Biblio
Export 30 results:
Author Title Type [ Year
] Filters: First Letter Of Last Name is T [Clear All Filters]
. Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson's Disease: Discovery and Characterization of New Inhibitors. European Journal of Pharmaceutical Sciences [Internet]. 2025;:107133. https://authors.elsevier.com/sd/article/S0928-0987(25)00132-0
Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB)
Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB). Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. American Journal of Transplantation [Internet]. 2015;16(4):1160-1172. http://onlinelibrary.wiley.com/doi/10.1111/ajt.13564/abstract
. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstract Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB) Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB) Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB)
Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB) Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB) Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB). The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. Anisimov 2013 Science Signaling (1.92 MB) Anisimov 2013 Science Signaling Supplement (2.09 MB)
Anisimov 2013 Science Signaling (1.92 MB) Anisimov 2013 Science Signaling Supplement (2.09 MB). Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2013;110(32):12960 - 12965. http://www.pnas.org/content/110/32/12960.long
. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. Anisimov 2013 (6.56 MB) Anisimov 2013 Supplement (4.93 MB)
Anisimov 2013 (6.56 MB) Anisimov 2013 Supplement (4.93 MB). Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. Anisimov 2013 (6.56 MB) Anisimov 2013 Supplement (4.93 MB)
Anisimov 2013 (6.56 MB) Anisimov 2013 Supplement (4.93 MB). Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am J Pathol. 2012;181(5):1607-20.
. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085 Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB) Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB) Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB). Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085 Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB) Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB) Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB). VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. Journal of Heart and Lung Transplantation. 2011;30:S118 - S118.
. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043 Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB) Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB) Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB). Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043 Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB) Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB)
Denis Tvorogov et al., Cancer Cell 2010 (1.3 MB) Denis Tvorogov et al., Cancer Cell 2010, supplement (828.69 KB). Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974 Maija Bry et al., Circulation 2010 (2.23 MB) Maija Bry et al., Circulation 2010, supplement (17.77 MB)
Maija Bry et al., Circulation 2010 (2.23 MB) Maija Bry et al., Circulation 2010, supplement (17.77 MB). Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699 Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB) Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB) Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB). Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733 Tuomas Tammela et al., Circulation Research 2007 (1.1 MB)
Tuomas Tammela et al., Circulation Research 2007 (1.1 MB). Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. Circ Res [Internet]. 2007;100(10):1460 - 7. http://view.ncbi.nlm.nih.gov/pubmed/17478734 Salla Keskitalo et al., Circulation Research 2007 (1.98 MB)
Salla Keskitalo et al., Circulation Research 2007 (1.98 MB). Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J [Internet]. 2006;20(9):1462 - 72. http://view.ncbi.nlm.nih.gov/pubmed/16816121 Terhi Kärpänen et al., FASEB Journal 2006 (2.51 MB)
Terhi Kärpänen et al., FASEB Journal 2006 (2.51 MB). Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734 Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292 Yulong He et al., Cancer Research 2005 (1.82 MB)
Yulong He et al., Cancer Research 2005 (1.82 MB). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646 Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646 Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB). Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res [Internet]. 2003;314(1):69 - 84. http://view.ncbi.nlm.nih.gov/pubmed/12942362 Michael Jeltsch et al., Cell and Tissue Research 2003 (562.33 KB)
Michael Jeltsch et al., Cell and Tissue Research 2003 (562.33 KB). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889 Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)
Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)